The National AIDS Commission (NAC) has raised serious concern over a steady increase in HIV cases across Liberia, revealing that the number of people living with the virus has climbed from 34,000 in ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...

Administration officials say South Africa has “significant means” to fund a promising new drug, lenacapavir, on its own.

The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Merck reports positive results from phase 3 trial of once-daily, oral, two-drug, single-tablet regimen of Doravirine/Islatravir in treatment-naïve adults with HIV-1 infection ...

The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...

Eswatini on Tuesday became the first African country to receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a ...

Today, Seema Sahay is Head of Division of Social Behavioural Research at the Indian Council of Medical Research, National Institute of Translational Virology & AIDS Research (NARI), Pune, India.

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...